Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Summary

This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die.

Timeline

Start

2004-09

Primary completion

2007-08

Completion

—

Drugs

Indications